No Love Lost between Viruses and Interferons

Annual Review of Virology

Volumn 2, Issue , 2015, Pages 549-572

  Fensterl, Volker ^a   Chattopadhyay, Saurabh ^a   Sen, Ganes C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiviral action; DsRNA; Innate immunity; Interferon stimulated gene; Interferon ; Pathogenesis; Pattern recognition receptor; Viral evasion; Virus infection

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 3; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ANTIVIRAL ACTIVITY; APOPTOSIS; CELLULAR IMMUNITY; CONFORMATIONAL TRANSITION; ENCEPHALOMYOCARDITIS VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; INFLUENZA A VIRUS; INNATE IMMUNITY; INTERFERON INDUCTION; INTERFERON PRODUCTION; INTRACELLULAR SIGNALING; MACROPHAGE; MURINE CYTOMEGALOVIRUS; NONHUMAN; NUCLEAR IMPORT; PALMITOYLATION; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; REOVIRIDAE; REVIEW; SUMOYLATION; UBIQUITINATION; VESICULOVIRUS; VIRUS ACTIVATION; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; WEST NILE VIRUS; ANIMAL; GENETICS; IMMUNOLOGY; VIROLOGY; VIRUS;

ANIMALS; HUMANS; IMMUNITY, INNATE; INTERFERONS; VIRUS DISEASES; VIRUSES;

EID: 84969221169     PISSN: 2327056X     EISSN: 23270578     Source Type: Journal    
DOI: 10.1146/annurev-virology-100114-055249     Document Type: Review

References (167)

1. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc. R. Soc. B 147:258-67
2. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: A complex web of host defenses. Annu. Rev. Immunol. 32:513-45
3. Versteeg GA, Garcia-Sastre A. 2010. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. 13:508-16
4. McNab F,Mayer-Barber K, Sher A,Wack A, O'Garra A. 2015. Type I interferons in infectious disease. Nat. Rev. Immunol. 15:87-103
5. de Weerd NA, Nguyen T. 2012. The interferons and their receptors-distribution and regulation. Immunol. Cell Biol. 90:483-91
6. O'Brien TR, Prokunina-Olsson L, Donnelly RP. 2014. IFN-λ4: The paradoxical new member of the interferon lambda family. J. Interferon Cytokine Res. 34:829-38
7. Pestka S, Krause CD, Walter MR. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202:8-32
8. Fitzgerald-Bocarsly P, Dai J, Singh S. 2008. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 19:3-19
9. Fung KY,ManganNE, Cumming H, Horvat JC,Mayall JR, et al. 2013. Interferon-εprotects the female reproductive tract from viral and bacterial infection. Science 339:1088-92
10. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. 2004. Characterization of the type I interferon locus and identification of novel genes. Genomics 84:331-45
11. MordsteinM,NeugebauerE,DittV, JessenB,RiegerT, et al. 2010. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84:5670-77
12. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, et al. 2014. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15:190-202
13. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-λ) is expressed in a tissuedependent fashion and primarily acts on epithelial cells in vivo. PLOS Pathog. 4:e1000017
14. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes differentially regulated by interferon α, β, or γusing oligonucleotide arrays. PNAS 95:15623-28
15. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, et al. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44:896-906
16. Decker T, Kovarik P,Meinke A. 1997. GAS elements: A few nucleotides with amajor impact on cytokineinduced gene expression. J. Interferon Cytokine Res. 17:121-34
17. Platanias LC. 2005. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5:375-86
18. Pestka S. 2007. The interferons: 50 years after their discovery, there ismuchmore to learn. J. Biol. Chem. 282:20047-51
19. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. 2003. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4:69-77
20. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4:63-68
21. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45:164-71
22. Key FM, Peter B, DennisMY, Huerta-Sanchez E, Tang W, et al. 2014. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLOS Genet. 10:e1004681
23. Pandey S, Kawai T, Akira S. 2015. Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors. Cold Spring Harb. Perspect. Biol. 7:a016246
24. Gay NJ, Symmons MF, Gangloff M, Bryant CE. 2014. Assembly and localization of Toll-like receptor signalling complexes. Nat. Rev. Immunol. 14:546-58
25. Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T. 2015. Viral RNA detection by RIG-I-like receptors. Curr. Opin. Immunol. 32:48-53
26. Wu J, Chen ZJ. 2014. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32:461-88
27. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, et al. 2001. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-69
28. Zarember KA, Godowski PJ. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168:554-61
29. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413:732-38
30. HardarsonHS, Baker JS, Yang Z, Purevjav E, Huang CH, et al. 2007. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am. J. Physiol.Heart Circ. Physiol. 292:H251-58
31. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, et al. 2006. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLOS Pathog. 2:e53
32. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, et al. 2007. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317:1522-27
33. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. 2007. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315:1398-401
34. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-5
35. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, et al. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. PNAS 103:8459-64
36. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, et al. 2014. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature 514:372-75
37. Weber M, Gawanbacht A, Habjan M, Rang A, Borner C, et al. 2013. Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling. Cell Host Microbe 13:336-46
38. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, et al. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiationassociated gene 5. J. Exp. Med. 205:1601-10
39. Zust R, Cervantes-Barragan L, HabjanM,Maier R, Neuman BW, et al. 2011. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 12:137-43
40. Bruns AM, LeserGP, Lamb RA,Horvath CM. 2014. The innate immune sensor LGP2 activates antiviral signaling by regulating MDA5-RNA interaction and filament assembly. Mol. Cell 55:771-81
41. Childs KS, Randall RE,Goodbourn S. 2013. LGP2 plays a critical role in sensitizingmda-5 to activation by double-stranded RNA. PLOS ONE 8:e64202
42. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, et al. 2007. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. PNAS 104:582-87
43. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, et al. 2004. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21:107-19
44. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. 2009. RIG-I-dependent sensing of poly (dA:dT) through the induction of anRNApolymerase III-transcribedRNAintermediate. Nat. Immunol. 10:1065-72
45. Chiu YH, Macmillan JB, Chen ZJ. 2009. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138:576-91
46. Unterholzner L. 2013. The interferon response to intracellular DNA: Why somany receptors? Immunobiology 218:1312-21
47. Chattopadhyay S, Sen GC. 2014. Tyrosine phosphorylation in Toll-like receptor signaling. Cytokine Growth Factor Rev. 25:533-41
48. Sarkar SN, Elco CP, Peters KL, Chattopadhyay S, Sen GC. 2007. Two tyrosine residues of Toll-like receptor 3 trigger different steps of NF-κB activation. J. Biol. Chem. 282:3423-27
49. Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, Sen GC. 2004. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat. Struct. Mol. Biol. 11:1060-67
50. Sarkar SN, Smith HL, Rowe TM, SenGC. 2003. Double-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain. J. Biol. Chem. 278:4393-96
51. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, et al. 2008. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 320:379-81
52. Yamashita M, Chattopadhyay S, Fensterl V, Saikia P, Wetzel JL, Sen GC. 2012. Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci. Signal. 5:ra50
53. Gack MU. 2014. Mechanisms of RIG-I-like receptor activation and manipulation by viral pathogens. J. Virol. 88:5213-16
54. Maharaj NP, Wies E, Stoll A, Gack MU. 2012. Conventional protein kinase C-α(PKC-α) and PKC-β negatively regulate RIG-I antiviral signal transduction. J. Virol. 86:1358-71
55. Wies E, Wang MK, Maharaj NP, Chen K, Zhou S, et al. 2013. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity 38:437-49
56. Gack MU, Shin YC, Joo CH, Urano T, Liang C, et al. 2007. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446:916-20
57. Zeng W, Sun L, Jiang X, Chen X, Hou F, et al. 2010. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 141:315-30
58. Cai X, Chiu YH, Chen ZJ. 2014. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol. Cell 54:289-96
59. Ford E, Thanos D. 2010. The transcriptional code of human IFN-βgene expression. Biochim. Biophys. Acta 1799:328-36
60. Panne D, Maniatis T, Harrison SC. 2007. An atomic model of the interferon-β enhanceosome. Cell 129:1111-23
61. Genin P, Vaccaro A, Civas A. 2009. The role of differential expression of human interferon-A genes in antiviral immunity. Cytokine Growth Factor Rev. 20:283-95
62. Iversen MB, Paludan SR. 2010. Mechanisms of type III interferon expression. J. Interferon Cytokine Res. 30:573-78
63. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, et al. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 282:7576-81
64. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. 2007. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes. J. Immunol. 179:3434-42
65. Broz P, Monack DM. 2013. Newly described pattern recognition receptors team up against intracellular pathogens. Nat. Rev. Immunol. 13:551-65
66. Andersen J, VanScoy S, Cheng TF, GomezD, Reich NC. 2008. IRF-3-dependent and augmented target genes during viral infection. Genes Immun. 9:168-75
67. Freaney JE, Kim R,Mandhana R, Horvath CM. 2013. Extensive cooperation of immune master regulators IRF3 andNFκB inRNAPol II recruitment and pause release in human innate antiviral transcription. Cell Rep. 4:959-73
68. Chattopadhyay S,Marques JT, YamashitaM, Peters KL, Smith K, et al. 2010. Viral apoptosis is induced by IRF-3-mediated activation of Bax. EMBO J. 29:1762-73
69. White CL, Chattopadhyay S, Sen GC. 2011. Phosphatidylinositol 3-kinase signaling delays Sendai virus-induced apoptosis by preventing XIAP degradation. J. Virol. 85:5224-27
70. Chattopadhyay S, Fensterl V, Zhang Y, Veleeparambil M, Yamashita M, Sen GC. 2013. Role of interferon regulatory factor 3-mediated apoptosis in the establishment and maintenance of persistent infection by Sendai virus. J. Virol. 87:16-24
71. Chattopadhyay S, Yamashita M, Zhang Y, Sen GC. 2011. The IRF-3/Bax-mediated apoptotic pathway, activated by viral cytoplasmic RNA and DNA, inhibits virus replication. J. Virol. 85:3708-16
72. Ivashkiv LB, Donlin LT. 2014. Regulation of type I interferon responses. Nat. Rev. Immunol. 14:36-49
73. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon-γ: An overview of signals, mechanisms and functions. J. Leukoc. Biol. 75:163-89
74. Durbin RK, Kotenko SV, Durbin JE. 2013. Interferon induction and function at the mucosal surface. Immunol. Rev. 255:25-39
75. Ng SL, Friedman BA, Schmid S, Gertz J, Myers RM, et al. 2011. IκB kinase ε (IKKε) regulates the balance between type I and type II interferon responses. PNAS 108:21170-75
76. Rajsbaum R, Versteeg GA, Schmid S, Maestre AM, Belicha-Villanueva A, et al. 2014. Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response. Immunity 40:880-95
77. Stark GR. 2007. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev. 18:419-23
78. Fish EN, Platanias LC. 2014. Interferon receptor signaling inmalignancy: A network of cellular pathways defining biological outcomes. Mol. Cancer Res. 12:1691-703
79. de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, et al. 2013. Structural basis of a unique interferon-βsignaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14:901-7
80. de Weerd NA, Samarajiwa SA, Hertzog PJ. 2007. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282:20053-57
81. Samarajiwa SA, Mangan NE, Hardy MP, Najdovska M, Dubach D, et al. 2014. Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock. J. Immunol. 192:4425-35
82. Gazziola C, CordaniN, Carta S, De Lorenzo E, Colombatti A, Perris R. 2005. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNαon pleomorphic sarcoma cells. Int. J. Oncol. 26:129-40
83. Malakhova OA, KimKI, Luo JK, ZouW,KumarKG, et al. 2006. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 25:2358-67
84. Piganis RA, de Weerd NA, Gould JA, Schindler CW, Mansell A, et al. 2011. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon αreceptor (IFNAR1)-associated tyrosine kinase Tyk2. J. Biol. Chem. 286:33811-18
85. CheonH,Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, et al. 2013. IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 32:2751-63
86. Kroczynska B, Mehrotra S, Arslan AD, Kaur S, Platanias LC. 2014. Regulation of interferon-dependent mRNA translation of target genes. J. Interferon Cytokine Res. 34:289-96
87. Mohr I, Sonenberg N. 2012. Host translation at the nexus of infection and immunity. Cell Host Microbe 12:470-83
88. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, et al. 2007. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J. Biol. Chem. 282:1757-68
89. Gonzalez-Navajas JM, Lee J,David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12:125-35
90. Schoggins JW. 2014. Interferon-stimulated genes: roles in viral pathogenesis. Curr. Opin. Virol. 6:40-46
91. Karki S, LiMM,Schoggins JW,Tian S, Rice CM,MacDonald MR. 2012. Multiple interferon stimulated genes synergize with the zinc finger antiviral protein to mediate anti-alphavirus activity. PLOS ONE 7:e37398
92. Schoggins JW,Wilson SJ, Panis M, Murphy MY, Jones CT, et al. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-85
93. Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, et al. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505:691-95
94. Fensterl V, Wetzel JL, Ramachandran S, Ogino T, Stohlman SA, et al. 2012. Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLOS Pathog. 8:e1002712
95. Bailey CC, Zhong G, Huang IC, Farzan M. 2014. IFITM-family proteins: The cell's first line of antiviral defense. Annu. Rev. Virol. 1:261-83
96. Haller O, Staeheli P, Schwemmle M, Kochs G. 2015. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol. 23:154-63
97. Li J, Ding SC, Cho H, Chung BC, Gale M Jr., et al. 2013. A short hairpin RNA screen of interferonstimulated genes identifies a novel negative regulator of the cellular antiviral response. mBio 4:e00385-13
98. Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G. 2012. Systematic identification of type I and type II interferon-induced antiviral factors. PNAS 109:4239-44
99. ChoH, Shrestha B, Sen GC, DiamondMS. 2013. A role for Ifit2 in restrictingWestNile virus infection in the brain. J. Virol. 87:8363-71
100. Fensterl V, Wetzel JL, Sen GC. 2014. Interferon-induced protein Ifit2 protects mice from infection of the peripheral nervous system by vesicular stomatitis virus. J. Virol. 88:10303-11
101. MacMicking JD. 2012. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. 12:367-82
102. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-68
103. Chakrabarti A, Jha BK, Silverman RH. 2011. New insights into the role of RNase L in innate immunity. J. Interferon Cytokine Res. 31:49-57
104. Malathi K, Dong B, Gale M Jr., Silverman RH. 2007. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 448:816-19
105. Fensterl V, Sen GC. 2011. The ISG56/IFIT1 gene family. J. Interferon Cytokine Res. 31:71-78
106. Fensterl V, Sen GC. 2015. Interferon-induced Ifit proteins: their role in viral pathogenesis. J. Virol. 89:2462-68
107. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, et al. 2010. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468:452-56
108. Habjan M, Hubel P,LacerdaL,Benda C, Holze C, et al. 2013. Sequestration by IFIT1 impairs translation of 2'O-unmethylated capped RNA. PLOS Pathog. 9:e1003663
109. Kumar P, Sweeney TR, Skabkin MA, Skabkina OV, Hellen CU, Pestova TV. 2014. Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5'-terminal regions of cap0-, cap1-and 5'ppp-mRNAs. Nucleic Acids Res. 42:3228-45
110. Pichlmair A, Lassnig C, Eberle CA, GornaMW, Baumann CL, et al. 2011. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat. Immunol. 12:624-30
111. Butchi NB, Hinton DR, Stohlman SA, Kapil P, Fensterl V, et al. 2014. Ifit2 deficiency results in uncontrolled neurotropic coronavirus replication and enhanced encephalitis via impaired alpha/beta interferon induction in macrophages. J. Virol. 88:1051-64
112. BlancM,Hsieh WY, Robertson KA, Kropp KA, Forster T, et al. 2013. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity 38:106-18
113. Civra A, Cagno V, Donalisio M, Biasi F, Leonarduzzi G, et al. 2014. Inhibition of pathogenic nonenveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol. Sci. Rep. 4:7487
114. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, et al. 2013. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 38:92-105
115. Durfee LA, LyonN, Seo K, Huibregtse JM. 2010. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell 38:722-32
116. Morales DJ, Lenschow DJ. 2013. The antiviral activities of ISG15. J. Mol. Biol. 425:4995-5008
117. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, et al. 2007. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. PNAS 104:1371-76
118. Morales DJ, Monte K, Sun L, Struckhoff JJ, Agapov E, et al. 2015. Novel mode of ISG15-mediated protection against influenza A virus and Sendai virus in mice. J. Virol. 89:337-49
119. Bogunovic D, Byun M, Durfee LA,Abhyankar A, SanalO, et al. 2012. Mycobacterial disease and impaired IFN-γimmunity in humans with inherited ISG15 deficiency. Science 337:1684-88
120. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, et al. 2015. Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature 517:89-93
121. Liberatore RA, Bieniasz PD. 2011. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. PNAS 108:18097-101
122. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-30
123. Swiecki M, Omattage NS, Brett TJ. 2013. BST-2/tetherin: structural biology, viral antagonism, and immunobiology of a potent host antiviral factor. Mol. Immunol. 54:132-39
124. Crow MK. 2014. Type I interferon in the pathogenesis of lupus. J. Immunol. 192:5459-68
125. Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE. 2012. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36:166-74
126. Karaghiosoff M, Steinborn R, Kovarik P, Kriegshauser G, Baccarini M, et al. 2003. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4:471-77
127. Davidson S, Crotta S, McCabe TM, Wack A. 2014. Pathogenic potential of interferon αβ in acute influenza infection. Nat. Commun. 5:3864
128. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, et al. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340:207-11
129. Wetzel JL, Fensterl V, Sen GC. 2014. Sendai virus pathogenesis in mice is prevented by Ifit2 and exacerbated by interferon. J. Virol. 88:13593-601
130. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, et al. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340:202-7
131. McCullers JA. 2014. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat. Rev. Microbiol. 12:252-62
132. Davidson S, MainiMK, Wack A. 2015. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J. Interferon Cytokine Res. 35:252-64
133. Baldridge MT, Nice TJ,McCune BT, Yokoyama CC, Kambal A, et al. 2015. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science 347:266-69
134. Nice TJ, Baldridge MT,McCune BT, Norman JM,LazearHM,et al. 2015. Interferon-λcures persistent murine norovirus infection in the absence of adaptive immunity. Science 347:269-73
135. Kernbauer E,Ding Y,Cadwell K. 2014. An enteric virus can replace the beneficial function of commensal bacteria. Nature 516:94-98
136. Welsch C, Jesudian A, Zeuzem S, Jacobson I. 2012. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(Suppl. 1):i36-46
137. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, et al. 2010. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52:822-32
138. Ramos EL. 2010. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J. Interferon Cytokine Res. 30:591-95
139. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, et al. 2011. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon αresponse. PLOS ONE 6:e22200
140. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. 2011. Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-αin vivo. Hepatology 53:1154-63
141. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, et al. 2009. Alpha interferon induces longlasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol. Cell. Biol. 29:4841-51
142. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. 2008. Interferon signaling and treatment outcome in chronic hepatitis C. PNAS 105:7034-39
143. Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, et al. 2014. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat. Commun. 5:5699
144. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. 2010. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52:1888-96
145. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. 2013. Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples. PLOS ONE 8:e84026
146. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, et al. 2014. Association of the IFNL4-βG allele with impaired spontaneous clearance of hepatitis C virus. J. Infect. Dis. 209:350-54
147. Randall RE, Goodbourn S. 2008. Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89:1-47
148. Cardenas WB, Loo YM, GaleMJr., Hartman AL, Kimberlin CR, et al. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80:5168-78
149. Krug RM. 2015. Functions of the influenza A virus NS1 protein in antiviral defense. Curr. Opin. Virol. 12:1-6
150. Santiago FW, Covaleda LM, Sanchez-Aparicio MT, Silvas JA, Diaz-Vizarreta AC, et al. 2014. Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic structures correlates with the inhibition of type I interferon responses. J. Virol. 88:4572-85
151. Goswami R,Majumdar T,Dhar J, Chattopadhyay S, Bandyopadhyay SK, et al. 2013. Viral degradasome hijacks mitochondria to suppress innate immunity. Cell Res. 23:1025-42
152. Horner SM, Gale M Jr. 2013. Regulation of hepatic innate immunity by hepatitis C virus. Nat. Med. 19:879-88
153. Childs K, Randall R, Goodbourn S. 2012. Paramyxovirus V proteins interact with the RNA helicase LGP2 to inhibit RIG-I-dependent interferon induction. J. Virol. 86:3411-21
154. Davis ME, Wang MK, Rennick LJ, Full F, Gableske S, et al. 2014. Antagonism of the phosphatase PP1 by the measles virus V protein is required for innate immune escape of MDA5. Cell Host Microbe 16:19-30
155. Mesman AW, Zijlstra-Willems EM, Kaptein TM, de Swart RL, Davis ME, et al. 2014. Measles virus suppresses RIG-I-like receptor activation in dendritic cells via DC-SIGN-mediated inhibition of PP1 phosphatases. Cell Host Microbe 16:31-42
156. Motz C, Schuhmann KM, Kirchhofer A, Moldt M, Witte G, et al. 2013. Paramyxovirus V proteins disrupt the fold of the RNA sensor MDA5 to inhibit antiviral signaling. Science 339:690-93
157. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, et al. 2009. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5:439-49
158. MibayashiM,Martinez-SobridoL, LooYM,CardenasWB, GaleMJr.,Garcia-Sastre A. 2007. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J. Virol. 81:514-24
159. Rajsbaum R, Albrecht RA, Wang MK, Maharaj NP, Versteeg GA, et al. 2012. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLOS Pathog. 8:e1003059
160. GerlierD,Lyles DS. 2011. Interplay between innate immunity and negative-strandRNAviruses: towards a rational model. Microbiol. Mol. Biol. Rev. 75:468-90
161. Li S, Min JY, Krug RM, Sen GC. 2006. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 349:13-21
162. Sharp TV, SchwemmleM, Jeffrey I, LaingK,MellorH, et al. 1993. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res. 21:4483-90
163. Zhang R, Jha BK, Ogden KM, Dong B, Zhao L, et al. 2013. Homologous 2',5'-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity. PNAS 110:13114-19
164. Diamond MS. 2014. IFIT1: A dual sensor and effector molecule that detects non-2'-O methylated viral RNA and inhibits its translation. Cytokine Growth Factor Rev. 25:543-50
165. Tang Y, Zhong G, Zhu L, Liu X, Shan Y, et al. 2010. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J. Immunol. 184:5777-90
166. Elde NC, Child SJ, Geballe AP, Malik HS. 2009. Protein kinase R reveals an evolutionary model for defeating viral mimicry. Nature 457:485-89
167. Navarini AA, Recher M, Lang KS, Georgiev P,Meury S, et al. 2006. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. PNAS 103:15535-39